FASE

Consolidated Financial Results for the Fiscal Year Ended December 31, 2023 [Japanese GAAP] February 13, 2024

							1 cordary 15, 2021
Company name:	Medical Data Vision Co., Ltd.					Listing: Tol	cyo Stock Exchange
Securities code:	3902 URL <u>https://www.</u>	.mdv.co.	<u>jp/</u>			0	
Representative:	(Title) President			(N	Jame) Hiroyuki Iwasaki		
Inquiries:	(Title) Executive Officer and	General	Manager of	(N	Jame) Masahiro Kihara	Tel: +	81-3-5283-6911
	Corporate Planning Di	ivision					
Scheduled date of	annual general meeting of sharehol	ders:]	March 27, 202		cheduled date to commence vidend payments:	March 28	3, 2024
Scheduled date to	file annual securities report:]	March 27, 202	24			
Preparation of sup	plementary material on financial re	sults :	Yes				
Holding of financ	ial results briefing	:	Yes (for in	nstitutio	nal investors and analysts)		
			(Yen amo	ounts are rounded down to r	nillions, unl	ess otherwise noted)
1. Consolidated fi	nancial results for the fiscal year en	ded Dec	ember 31, 202	23 (from	January 1, 2023 to Decemb	ber 31, 2023)
(1) Consolidated of	operating results				(Percentage	s indicate ye	ar-on-year changes)
						37.1	

	Net sale	5	Operating in	come	Ordinary in	come	Net income attrib owners of pa	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Fiscal year ended December 31, 2023 Fiscal year ended	6,419	5.2	1,770	0.7	1,700	-2.9	979	12.5
December 31, 2022	6,104	_	1,758	_	1,750		870	_

(Note) Comprehensive income F

Fiscal year ended December 31, 2023¥936million [11.8 %]Fiscal year ended December 31, 2022¥837 million [- %]

	Basic earnings per	Diluted earnings per	Return on equity	Ratio of ordinary	Ratio of operating
	share	share	Return on equity	income to total assets	income to net sales
	Yen	Yen	%	%	%
Fiscal year ended					
December 31, 2023	25.63	—	25.2	30.6	27.6
Fiscal year ended					
December 31, 2022	22.77	22.76	24.2	34.0	28.8
(Defenence) Shame of	musfit (loss) of antition of	accumted for using acquite	mothed Eigenlyssen an	dad Daamahan 21, 2022	72 million you

(Reference) Share of profit (loss) of entities accounted for using equity method Fiscal year ended December 31, 2023 -72 million yen Fiscal year ended December 31, 2022 — million yen

(Note) 1. The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29) and related implementation guidance have been applied from the beginning of the fiscal year ended December 2022. Consolidated earnings for the fiscal year ended December 2022, therefore, are the amount after applying such accounting standard and related implementation guidance, presenting no change from the previous corresponding period.

2. Diluted earnings per share for the fiscal year ended December 31, 2023 are not presented as there are no potentially dilutive shares.

(2) Consolidated financial position

(-) concontantea in	inite init population			
	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
Fiscal year ended				
December 31, 2023	6,221	4,317	68.3	111.21
Fiscal year ended				
December 31, 2022	4,897	3,606	71.8	92.04
(Reference) Equity	Fiscal year ended December 3	1, 2023 4,247 million yen		

Fiscal year ended December 31, 2022 3,515 million year

(3) Consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Fiscal year ended December 31, 2023 Fiscal year ended	1,616	-437	-225	3,218
December 31, 2022	910	-868	-979	2,264

2. Cash dividends

		Annua	al dividends per	share		Total cash		Ratio of
	First quarter-end	Second quarter- end	Third quarter- end	Fiscal year-end	Total	dividends (total)	Payout ratio (consolidated)	dividends to net assets (consolidated)
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended December 31, 2022 Fiscal year ended December 31, 2023	_	0.00 0.00		6.00 6.50		-		_
Fiscal year ending December 31, 2024 (forecast)	_	0.00		6.50			24.8	

3. Consolidated earnings forecasts for the fiscal year ending December 31, 2024 (from January 1, 2024 to December 31, 2024)

							(Perce	entages indicate	year-on-year changes)
	Net sa	lles	Operating	income	Ordinary	income	Net income a to owners of		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	8,000	24.6	1,630	-8.0	1,540	-9.4	1,000	2.1	26.18

* Notes

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in changes in scope of consolidation): None Newly included: — companies (Company name) , Excluded: - companies (Company name)

(2) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations : Yes

(ii) Changes in accounting policies due to other reasons : None : Yes

(iii) Changes in accounting estimates

(iv) Restatement

(Notes) For more details, please refer to "(5) Notes to consolidated financial statements (Change in accounting policies) and (Change in accounting estimates) in 3. Consolidated financial statements and Key notes" on page 7 of the attached materials.

: None

(3) Number of issued shares (common shares)

(i)	Total number of issued shares at the end of the period (including treasury shares)		40,027,526 shares	As of December 31, 2022	40,027,526 shares
(ii)	Number of treasury shares at the end of the period	As of December 31, 2023	1,830,678 shares	As of December 31, 2022	1,830,678 shares
(iii)	Average number of shares outstanding during the period	Fiscal year ended December 31, 2023	38,196,848 shares	Fiscal year ended December 31, 2022	38,234,269 shares

(Reference) Overview of non-consolidated financial results

Non-consolidated financial results for the fiscal year ended December 31, 2023(from January 1, 2023to December 31, 2023

(1) Non-consolidated operating results

(1) Non-consondated ope	failing results					(i cice	mages muleate yea	1-011-year changes)
	Net	sales	Operating	g income	Ordinary	v income	Net in	come
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Fiscal year ended December 31, 2023 Fiscal year ended	5,569	9.3	1,890	8.8	1,894	9.5	1,002	20.5
December 31, 2022	5,093	-	1,737	_	1,730	_	831	_

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Fiscal year ended		
December 31, 2023	26.25	—
Fiscal year ended		
December 31, 2022	21.76	_

(Note) 1. The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29) and related implementation guidance have been applied from the beginning of the fiscal year ended December 2022. Non-Consolidated earnings for the fiscal year ended December 2022, therefore, are the amount after applying such accounting standard and related implementation guidance, presenting no change from the previous corresponding period.

2 Diluted earnings per share for the fiscal year ended December 31, 2022 are not presented as there are no potential shares. Diluted earnings per share for the fiscal year ended December 31, 2023 are not presented as there are no potentially dilutive shares.

(Percentages indicate year-on-year changes)

(2) Non-consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
Fiscal year ended				
December 31, 2023	5,967	4,268	71.5	111.66
Fiscal year ended				
December 31, 2022	4,579	3,509	76.6	91.88
(Reference) Equity	Fiscal year ended December 3	31, 2023 ¥4,265million	December 31, 2022 ¥3,509m	nillion

* Financial results reports are exempt from an audit conducted by certified public accountants or an audit corporation.

* Proper use of earnings forecasts, and other special matters The forward-looking statements, including earnings forecasts, contained in this material are based on information currently available to the Group and on certain assumptions deemed to be reasonable. Actual business and other results may differ substantially due to a range of factods.

1. Consolidated financial statements and key notes (1) Consolidated balance sheet

		(Thousands of yen)
	Previous fiscal year (December 31, 2022)	Current fiscal year (December 31, 2023)
Assets		
Current assets		
Cash and deposits	2,264,855	3,218,073
Accounts receivable - trade	967,006	1,107,764
Contract assets	16,658	16,278
Raw materials	13,745	6,082
Other	265,272	318,553
Allowance for doubtful accounts	-2,999	-4,530
Total current assets	3,524,539	4,662,221
Non-current assets		
Property, plant and equipment		
Facilities attached to buildings, net	58,028	66,23
Tools, furniture and fixtures, net	79,248	92,283
Other, net	479	-
Total property, plant and equipment	* 137,755	* 158,52
Intangible assets		
Software	2,060	810
Goodwill	257,205	89,898
Other	192	-
Total intangible assets	259,459	90,70
Investments and other assets		
Investment securities	409,922	689,680
Deferred tax assets	324,779	344,059
Other	266,163	328,08
Allowance for doubtful accounts	-25,243	-52,059
Total investments and other assets	975,622	1,309,765
Total non-current assets	1,372,837	1,558,995
Total assets	4,897,377	6,221,210

		(Thousands of yen)
	Previous fiscal year (December 31, 2022)	Current fiscal year (December 31, 2023)
Liabilities		
Current liabilities		
Accounts payable - trade	93,155	140,587
Income taxes payable	95,786	478,212
Contract liabilities	755,426	769,310
Provision for bonuses	4,894	5,952
Other	257,529	411,450
Total current liabilities	1,206,791	1,805,513
Non-current liabilities		
Asset retirement obligations	71,554	85,885
Other	12,744	12,744
Total non-current liabilities	84,298	98,629
– Total liabilities	1,291,090	1,904,142
Net assets		
Shareholders' equity		
Share capital	992,661	992,661
Capital surplus	1,838,890	1,838,890
Retained earnings	3,045,575	3,795,519
Treasury shares	-2,341,975	-2,341,975
Total shareholders' equity	3,535,151	4,285,096
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	-19,503	-37,323
Total accumulated other comprehensive income	-19,503	-37,323
Share acquisition rights		3,491
Non-controlling interests	90,639	65,810
Total net assets	3,606,287	4,317,074
Total liabilities and net assets	4,897,377	6,221,216

(2) Consolidated statement of income and consolidated statement of comprehensive income

(Consolidated statement of income)

	Previous fiscal year (From January 1, 2022)	Current fiscal year (From January 1, 2023)
Net sales	to December 31, 2022) 6,104,599	to December 31, 2023) 6,419,026
Cost of sales	1,074,564	1,388,024
Gross income	5,030,034	5,031,002
Selling, general and administrative expenses	3,271,981	3,260,081
Operating income	1,758,053	1,770,921
Non-operating income	1,750,055	1,770,921
Interest income	157	62
Consumption taxes refund	1,017	_
Subsidy income	356	13
Dividend income	0	563
Reversal of allowance for doubtful accounts	684	684
Other	91	754
Total non-operating income	2,307	2,07
Non-operating expenses		
Commission expenses	9,343	-
Share of loss of entities accounted for using equity method	_	72,42
Other	68	154
Total non-operating expenses	9,412	72,579
Ordinary income	1,750,949	1,700,418
Extraordinary income		
Gain on sale of investment securities	51,538	_
Gain on reversal of share acquisition rights	_	72
Total extraordinary income	51,538	72
Extraordinary losses		
Loss on retirement of non-current assets	175	1,096
Loss on valuation of investment securities		15,874
Impairment losses	* 375,728	* 115,590
Total extraordinary losses	375,904	132,567
Net income before income taxes	1,426,583	1,567,922
Income taxes - current	375,021	625,037
Income taxes - deferred	194,495	-11,412
Total income taxes	569,516	613,624
Net income	857,066	954,297
Net income attributable to non-controlling interests	-13,442	-24,828
Net income attributable to owners of parent	870,509	979,125

(Consolidated statement of comprehensive income)

(Consolidated statement of comprehensive medine)		(Thousands of yen)
	Previous fiscal year (From January 1, 2022 to December 31, 2022)	Current fiscal year (From January 1, 2023 to December 31, 2023)
Net income	857,066	954,297
Other comprehensive income		
Valuation difference on available-for-sale securities	-19,503	-17,820
Total other comprehensive income	-19,503	-17,820
Comprehensive income	837,563	936,477
Comprehensive income attributable to:		
Owners of parent	851,006	961,305
Non-controlling interests	-13,442	-24,828

(3) Consolidated statement of changes in equity

Previous fiscal year (from January 1, 2022 to December 31, 2022)

	1					1		(T	housands of yen
		S	hareholders' equi	ity		Accumulated other comprehensive income			
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity	Valuation difference on available-for- sale securities	Total accumulated other comprehensive income	Non-controlling interests	Total net assets
Balance at beginning of period	992,661	1,763,567	2,879,722	-1,479,444	4,156,506	-	_	49,351	4,205,858
Cumulative effects of changes in accounting policies			-486,478		-486,478				-486,478
Restated balance	992,661	1,763,567	2,393,243	-1,479,444	3,670,028	-	_	49,351	3,719,380
Changes during period									
Dividends of surplus			-218,178		-218,178				-218,178
Net income attributable to owners of parent			870,509		870,509				870,509
Capital increase of consolidated subsidiaries		75,322			75,322				75,322
Purchase of treasury shares				-862,530	-862,530				-862,530
Net changes in items other than shareholders' equity						-19,503	-19,503	41,287	21,783
Total changes during period	-	75,322	652,331	-862,530	-134,876	-19,503	-19,503	41,287	-113,092
Balance at end of period	992,661	1,838,890	3,045,575	-2,341,975	3,535,151	-19,503	-19,503	90,639	3,606,287

Current fiscal year (from January 1, 2023 to December 31, 2023)

									(The	ousands of yen)
	Shareholders' equity		Accumulated other comprehensive income Issuance							
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity	Valuation difference on available-for- sale securities	Total accumulated other comprehensive income	share acquisition rights	Non- controlling interests	Total net assets
Balance at beginning of period	992,661	1,838,890	3,045,575	-2,341,975	3,535,151	-19,503	-19,503	_	90,639	3,606,287
Changes during period										
Dividends of surplus			-229,181		-229,181					-229,181
Net income attributable to owners of parent			979,125		979,125					979,125
Net changes in items other than shareholders' equity						-17,820	-17,820	3,491	-24,828	-39,157
Total changes during period			749,944		749,944	-17,820	-17,820	3,491	-24,828	710,787
Balance at end of period	992,661	1,838,890	3,795,519	-2,341,975	4,285,096	-37,323	-37,323	3,491	65,810	4,317,074

(4) Consolidated statement of cash flows

		(Thousands of yen)
	Previous fiscal year (From January 1, 2022	Current fiscal year (From January 1, 2023
	to December 31, 2022)	to December 31, 2023)
Cash flows from operating activities		
Net income before income taxes	1,426,583	1,567,922
Depreciation	62,511	48,828
Amortization of goodwill	87,483	53,192
Impairment losses	375,728	115,596
Increase (decrease) in allowance for doubtful accounts	47	28,346
Increase (decrease) in provision for bonuses	-23,964	1,058
Interest and dividend income	-158	-62:
Loss on retirement of non-current assets	175	1,090
Share of loss (profit) of entities accounted for using equity method	-	72,425
Loss (gain) on valuation of investment securities	_	15,874
Loss (gain) on sale of investment securities	-51,538	-
Decrease (increase) in trade receivables and	282.021	1(7.07)
contract assets	-282,921	-167,87
Decrease (increase) in inventories	-820	10,76
Increase (decrease) in trade payables	-4,111	47,432
Increase (decrease) in accounts payable - other	1,498	33,433
Increase (decrease) in accrued expenses	-961	3,54
Increase (decrease) in contract liabilities	6,042	13,88
Other	-14,625	29,44
Subtotal	1,580,969	1,874,34
Interest and dividends received	158	62
Income taxes refund (paid)	-670,332	-258,65
Net cash provided by (used in) operating activities	910,795	1,616,31
Cash flows from investing activities		
Payments into time deposits	-800	-
Proceeds from withdrawal of time deposits	20,418	-
Purchase of property, plant and equipment	-53,244	-30,20
Proceeds from sale and redemption of investment securities	60,000	-
Purchase of short-term and long-term investment securities	-411,600	-393,74
Purchase of shares of subsidiaries resulting in change in scope of consolidation	-467,090	-
Payments of leasehold deposits	-31,138	-50,06
Proceeds from refund of leasehold deposits	15,630	33,53
Payments of loans receivable	-200,000	-30,00
Proceeds from collection of loans receivable	200,000	30,00
Other	-927	2,65
Net cash provided by (used in) investing activities	-868,752	-437,83
Cash flows from financing activities		
Proceeds from issuance of share acquisition rights	_	3,56
Purchase of treasury shares	-871,874	-
Proceeds from share issuance to non-controlling shareholders	110,200	-
Dividends paid	-217,685	-228,82
Net cash provided by (used in) financing activities	-979,359	-225,264
Net increase (decrease) in cash and cash equivalents	-937,316	953,21
Cash and cash equivalents at beginning of period	3,202,172	2,264,85
Cash and cash equivalents at end of period	2,264,855	3,218,07

(5) Notes to consolidated financial statements

(Notes to assumptions for on going concerns)

Not applicable

(Changes in accounting policies)

(Application of Implementation Guidance on Accounting Standard for Fair Value Measurement)

The Company has applied the "Implementation Guidance on Accounting Standard for Fair Value Measurement" (ASBJ Guidance No. 31, June 17, 2021; hereinafter referred to as the "Guidance on Accounting Standard for Fair Value Measurement") will be applied from the beginning of the first quarter of the current fiscal year, and the new accounting policy stipulated by the Implementation Guidance on Accounting Standard for Fair Value Measurement will be applied in the future in accordance with the transitional treatment stipulated in Article 27-2 of the Guidance on Accounting Standard for Fair Value Measurement. This has no effect on the consolidated financial statements.

(Change in Accounting Estimates)

(Change in Estimates of Asset Retirement Obligations)

During the fiscal year under review, the Company changed its estimate of asset retirement obligations, which had been recorded as a restoration obligation under the lease agreement for a real estate, in accordance with the availability of new information on restoration costs. As a result of this change, the balance of asset retirement obligations increased by 14,034 thousands of yen. This has no effect on the profit and loss.

(Consolidated balance sheet)

* Accumulated depreciation of property, plant and equipment is as follows:

	Previous fiscal year	Current fiscal year
	(From January 1, 2022	(From January 1, 2023
	to December 31, 2022)	to December 31, 2023)
Accumulated depreciation of property, plant and	542,116	579,702
equipment	(thousands of yen)	(thousands of yen)

(Consolidated statement of income)

Details of impairment losses are as follows:

Previous fiscal year (from January 1, 2022 to December 31, 2022)

The Group recorded impairment losses on the following asset groups.

Location	Application	Туре	Amount (thousands of yen)
Shinagawa-ku, Tokyo	Business assets	Facilities attached to buildings, etc.	1,272
Shinagawa -ku, Tokyo	Other	Goodwill	342,386
Shinagawa -ku, Tokyo	Business assets	Technology related assets	32,069

In principle, the Group groups its assets according to the category of management accounting based on business units. However, assets that are not likely to be used in the future or for which a decision has been made to dispose of or discontinue them are grouped individually. With regard to AIR BIOS Co., Ltd., our consolidated subsidiary, we changed our policy from in-house integrated planning and operation to tie-up with companies with facilities, know-how, sales channels, etc. As a result of reviewing our future business plans, progress was delayed compared to the initial business plans, and we no longer expect revenue within the originally anticipated time frame. As a result, the entire book value of goodwill, etc. related to the Company was recorded as an impairment loss. The recoverable amount of the said asset group is measured by the value in use. Since negative future cash flows are expected, the recoverable amount is calculated as zero.

Current fiscal year (from January 1, 2023 to December 31, 2023)

The Group recorded impairment losses on the following asset groups.

Location	Application	Туре	Amount (thousands of yen)
Chiyoda -ku, Tokyo	Other	Goodwill	78,012
Fukuoka City Fukuoka	Other	Goodwill	36,102
Fukuoka City Fukuoka	Business assets	Tools, furniture and fixtures, etc.	1,481

In principle, the Group groups its assets according to the category of management accounting based on business units. However, assets that are not likely to be used in the future or for which a decision has been made to dispose of or discontinue them are grouped individually. With regard to Doctor book Co., Ltd., our consolidated subsidiary, have decided that we will no longer use business assets related to online medical treatment held in the dental field. As a result, the entire book value of goodwill related to these was recorded as an impairment loss. Also, with regard to System be alpha Co., Ltd., our consolidated subsidiary, consider carefully our future business plans, As a result of we no longer expect revenue within the originally anticipated time frame. As a result, the entire book value of goodwill, etc. related to these was recorded as an impairment loss. The recoverable amount of the said asset group is measured by the value in use. Since negative future cash flows are expected, the recoverable amount is calculated as zero.

(Segment information, etc.)

Segment information

Segment information is omitted as the Group is comprised of a single segment of the medical data network business.

(Per-share information)

	Previous fiscal year (From January 1, 2022 to December 31, 2022)	Current fiscal year (From January 1, 2023 to December 31, 2023)
Net assets per share	92.04 yen	111.21 yen
Basic earnings per share	22.77 yen	25.63 yen
Diluted earnings per share	22.76 yen	— yen

(Notes)1. Diluted earnings per share for the current fiscal year is not presented as there are no potentially dilutive shares.2. The calculation basis earnings per share and diluted earnings per share is as follows:

	Previous fiscal year (From January 1, 2022 to December 31, 2022)	Current fiscal year (From January 1, 2023 to December 31, 2023)
Basic earnings per share		
Net income attributable to owners of parent (thousands of yen)	870,509	979,125
Amount not attributable to common shareholders (thousands of yen)	_	_
Net income attributable to owners of parent concerning common shares (thousands of yen)	870,509	979,125
Average number of shares outstanding during the period (shares)	38,234,269	38,196,848
Diluted earnings per share		
Adjustments to profit attributable to owners of parent (thousands of yen)	-449	-
(Of which, adjustments by dilutive shares of consolidated subsidiaries (thousands of yen)	-449	-
Increase in common stock	_	-
Descriptions of potentially dilutive common shares that were not included in the calculation of net income because of their anti-dilutive effect	Consolidated subsidiary Doctorbook Inc. Third round of share acquisition rights Common stock 270 shares Fourth round of share acquisition rights Common stock 90 shares Fifth round of share acquisition rights Common stock 480 shares Sixth round of share acquisition rights Common stock 60 shares Seventh round of share acquisition rights Common stock 40 shares	Company submitting Fourth round of share acquisition rights Common stock 3,879 shares Consolidated subsidiary Doctorbook Inc. First round of share acquisition rights Common stock 1,250 shares Third round of share acquisition rights Common stock 70 shares Fourth round of share acquisition rights Common stock 90 shares Fifth round of share acquisition rights Common stock 350 shares Sixth round of share acquisition rights Common stock 60 shares Seventh round of share acquisition rights Common stock 60 shares

(Important subsequent events) Not applicable

2. Other

(1) Changes in officers (expected on March 27, 2024)

- (i) Change in representative directors
 - Not applicable

(ii) Change in other officers

New appointed director
Kiyomi Nojiri Outside Director

 Retiring Corporate Auditor Atsushi Igarashi Outside Corporate Auditor

(2) Other

Not applicable